Trial Profile
Study of oral neurokinin-1 antagonist, aprepitant for the prevention of nausea and vomiting in patients receiving chemotherapy with irinotecan alone or combination of irinotecan plus cisplatin for unresectable gastric cancer
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 18 May 2016
Price :
$35
*
At a glance
- Drugs Aprepitant (Primary) ; Dexamethasone; Granisetron
- Indications Gastric cancer
- Focus Therapeutic Use
- 18 May 2016 New trial record